Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation Dec 20, 2023
Awakn’s Dr. Ben Sessa: Ketamine Assisted Therapy Providing “Breakthrough, Transformative Experience” Jan 31, 2023
Awakn Life Sciences’ Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66%… Jul 20, 2022
Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead… Jul 5, 2022
Awakn Life Sciences Appoints Biotech and Investment Veteran Dennis Purcell as a Special Advisor to the CEO Jun 7, 2022
